Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

PURPOSE: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). DESIGN: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial i...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar:	Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2012

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial Yazar: Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Baskı/Yayın Bilgisi 2012

Journal article

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial Yazar: Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Benzer Materyaller